NASDAQ:CBLICleveland BioLabs Competitors & Alternatives

Cleveland BioLabs (NASDAQ:CBLI) and Iqvia (NYSE:IQV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Iqvia, as provided by MarketBeat.com.

Iqvia has a consensus price target of $153.7333, indicating a potential upside of 8.63%. Given Iqvia's higher probable upside, analysts clearly believe Iqvia is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 88.6% of Iqvia shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Iqvia's net margins, return on equity and return on assets.

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Iqvia's revenue, earnings per share (EPS) and valuation.

Iqvia has higher revenue and earnings than Cleveland BioLabs.

Summary

Iqvia beats Cleveland BioLabs on 10 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Incyte, as provided by MarketBeat.com.

Incyte has a consensus price target of $100.65, indicating a potential downside of 5.47%. Given Incyte's higher probable upside, analysts clearly believe Incyte is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 91.3% of Incyte shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 16.1% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Incyte's net margins, return on equity and return on assets.

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Incyte's revenue, earnings per share (EPS) and valuation.

Incyte has higher revenue and earnings than Cleveland BioLabs.

Summary

Incyte beats Cleveland BioLabs on 10 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and EXACT Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and EXACT Sciences, as provided by MarketBeat.com.

EXACT Sciences has a consensus price target of $107.3333, indicating a potential upside of 23.86%. Given EXACT Sciences' higher probable upside, analysts clearly believe EXACT Sciences is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 86.9% of EXACT Sciences shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 1.8% of EXACT Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and EXACT Sciences' net margins, return on equity and return on assets.

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, EXACT Sciences has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and EXACT Sciences' revenue, earnings per share (EPS) and valuation.

Cleveland BioLabs has higher earnings, but lower revenue than EXACT Sciences.

Summary

EXACT Sciences beats Cleveland BioLabs on 8 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and PPD (NASDAQ:PPD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and PPD, as provided by MarketBeat.com.

PPD has a consensus price target of $31.1429, indicating a potential upside of 15.86%. Given PPD's higher probable upside, analysts clearly believe PPD is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 65.5% of PPD shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and PPD's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cleveland BioLabs and PPD's revenue, earnings per share (EPS) and valuation.

PPD has higher revenue and earnings than Cleveland BioLabs.

Summary

PPD beats Cleveland BioLabs on 8 of the 10 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Icon (NASDAQ:ICLR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Icon, as provided by MarketBeat.com.

Icon has a consensus price target of $159.1818, indicating a potential downside of 4.63%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 82.7% of Icon shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Icon's net margins, return on equity and return on assets.

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Icon has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Icon's revenue, earnings per share (EPS) and valuation.

Icon has higher revenue and earnings than Cleveland BioLabs.

Summary

Icon beats Cleveland BioLabs on 9 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Charles River Laboratories Intl. (NYSE:CRL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Charles River Laboratories Intl., as provided by MarketBeat.com.

Charles River Laboratories Intl. has a consensus price target of $176.8333, indicating a potential downside of 0.05%. Given Charles River Laboratories Intl.'s higher probable upside, analysts clearly believe Charles River Laboratories Intl. is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 93.1% of Charles River Laboratories Intl. shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories Intl. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Charles River Laboratories Intl.'s net margins, return on equity and return on assets.

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Charles River Laboratories Intl. has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Charles River Laboratories Intl.'s revenue, earnings per share (EPS) and valuation.

Charles River Laboratories Intl. has higher revenue and earnings than Cleveland BioLabs.

Summary

Charles River Laboratories Intl. beats Cleveland BioLabs on 11 of the 12 factors compared between the two stocks.